Objective The aim of this study was to investigate the expression of microRNA?100 ( miR?100) and its relation with prognosis in colorectal cancer ( CRC) . Methods The expression of miR?100 was analyzed by quantitative real?time PCR ( qRT?PCR) in 172 CRC tissue samples. The relation of miR?100 expression patterns with clinical pathological significance in CRC was analyzed. The effects of alterations of miR?100 expression and its consequences on CRC cell proliferation, apoptosis and migration were demonstrated in cells cultured in vitro. Results The relative expression of miR?100 in CRC tissues and peritumoral tissues were -6. 185 ± 1. 921 and -3. 698 ± 1. 786, respectively, with a significant difference between the two groups( P<0.01) . There was a significant difference between the relative expression of miR?100 in CRC with lymph node metastasis (-5.706±1.809) and without lymph node metastasis (-6.775± 1.902, P<0.01). The relative expression of miR?100 in tumors of different TNM stages were -7.267±1.888 in stage Ⅰ, -6.443±1.859 in stageⅡ,-5.923±1.796 in stageⅢ, and-4.639±1.516 in stageⅣ, with a significant difference among them(P<0.01). Different differentiation grades showed different expression of miR?100, i.e. -7. 389 ± 1. 828 in well differentiated tumors, -6. 095 ± 1. 843 in moderately differentiated tumors, and -5.476±2.088 in poorly differentiated tumors (P<0.01). There was no significant correlation between miR?100 expression and overall survival rates of the CRC patients (P=0.179). Overexpression of miR?100 in the CRC cell line HCT?8 inhibited cell proliferation, but promoted cell apoptosis and migration. Conclusions The expression of miR?100 is correlated with lymph node metastasis, TNM stage and differentiation grade, and may be a potential biomarker indicating the development of CRC.

Objective The aim of this study was to investigate the expression of microRNA?100 ( miR?100) and its relation with prognosis in colorectal cancer ( CRC) . Methods The expression of miR?100 was analyzed by quantitative real?time PCR ( qRT?PCR) in 172 CRC tissue samples. The relation of miR?100 expression patterns with clinical pathological significance in CRC was analyzed. The effects of alterations of miR?100 expression and its consequences on CRC cell proliferation, apoptosis and migration were demonstrated in cells cultured in vitro. Results The relative expression of miR?100 in CRC tissues and peritumoral tissues were -6. 185 ± 1. 921 and -3. 698 ± 1. 786, respectively, with a significant difference between the two groups( P<0.01) . There was a significant difference between the relative expression of miR?100 in CRC with lymph node metastasis (-5.706±1.809) and without lymph node metastasis (-6.775± 1.902, P<0.01). The relative expression of miR?100 in tumors of different TNM stages were -7.267±1.888 in stage Ⅰ, -6.443±1.859 in stageⅡ,-5.923±1.796 in stageⅢ, and-4.639±1.516 in stageⅣ, with a significant difference among them(P<0.01). Different differentiation grades showed different expression of miR?100, i.e. -7. 389 ± 1. 828 in well differentiated tumors, -6. 095 ± 1. 843 in moderately differentiated tumors, and -5.476±2.088 in poorly differentiated tumors (P<0.01). There was no significant correlation between miR?100 expression and overall survival rates of the CRC patients (P=0.179). Overexpression of miR?100 in the CRC cell line HCT?8 inhibited cell proliferation, but promoted cell apoptosis and migration. Conclusions The expression of miR?100 is correlated with lymph node metastasis, TNM stage and differentiation grade, and may be a potential biomarker indicating the development of CRC.

OBJECTIVEThe aim of this study was to investigate the expression of microRNA-100 (miR-100) and its relation with prognosis in colorectal cancer (CRC).

METHODSThe expression of miR-100 was analyzed by quantitative real-time PCR (qRT-PCR) in 172 CRC tissue samples. The relation of miR-100 expression patterns with clinical pathological significance in CRC was analyzed. The effects of alterations of miR-100 expression and its consequences on CRC cell proliferation, apoptosis and migration were demonstrated in cells cultured in vitro.

RESULTSThe relative expression of miR-100 in CRC tissues and peritumoral tissues were -6.185 ± 1.921 and -3.698 ± 1.786, respectively, with a significant difference between the two groups (P<0.01). There was a significant difference between the relative expression of miR-100 in CRC with lymph node metastasis (-5.706 ± 1.809) and without lymph node metastasis (-6.775 ± 1.902, P<0.01). The relative expression of miR-100 in tumors of different TNM stages were -7.267 ± 1.888 in stage I, -6.443 ± 1.859 in stage II, -5.923 ± 1.796 in stage III, and -4.639 ± 1.516 in stage IV, with a significant difference among them (P<0.01). Different differentiation grades showed different expression of miR-100, i.e. -7.389 ± 1.828 in well differentiated tumors, -6.095 ± 1.843 in moderately differentiated tumors, and -5.476 ± 2.088 in poorly differentiated tumors (P<0.01). There was no significant correlation between miR-100 expression and overall survival rates of the CRC patients (P=0.179). Overexpression of miR-100 in the CRC cell line HCT-8 inhibited cell proliferation, but promoted cell apoptosis and migration.

CONCLUSIONSThe expression of miR-100 is correlated with lymph node metastasis, TNM stage and differentiation grade, and may be a potential biomarker indicating the development of CRC.

Apoptosis ; Cell Differentiation ; Cell Proliferation ; Colorectal Neoplasms ; metabolism ; mortality ; pathology ; Gene Expression Regulation, Neoplastic ; Humans ; Lymphatic Metastasis ; MicroRNAs ; metabolism ; Neoplasm Staging ; Prognosis ; Real-Time Polymerase Chain Reaction

OBJECTIVEThe aim of this study was to identify six miRNAs expressed in plasma of patients with pancreatic cancer (PCa) and analyze their value as a diagnostic index of pancreatic cancer.

METHODSPlasma total RNAs were extracted from 30 PCa patients and 26 normal controls, and the abundance of six microRNAs was measured using real-time PCR. The possibility to combine them with CA19-9 as diagnostic biomarkers was analyzed.

RESULTSThe expression level of miR-21, miR-210, miR-155, miR-20a, miR-25 and miR-196a in plasma of patients with pancreatic cancer were 1.65×10(6), 5.98×10(4), 2.83×10(3), 3.47×10(6), 2.76×10(6), and 1.03×10(3) (copies/µl), while the normal controls were 4.08×10(5), 2.54×10(4), 8.55×10(2), 1.79×10(6), 9.32×10(5), and 4.67×10(2) (copies/µl), respectively, with a significant difference between the two groups (P < 0.05). The areas under the ROC curve of miR-21, miR-210, miR-155, miR-20a, miR-25 and miR-196a were 0.893, 0.810, 0.820, 0.766, 0.816 and 0.729, respectively. MiR-21 had the highest diagnostic value when it was used as diagnostic marker alone. The combination of miR-155 and miR-25 was more effective to distinguish PCa from normal than to be used alone, and the area under the ROC curve was 0.913 (95%CI 0.838-0.988) .When CA199 associated with miR -210 and miR-25, respectively, the areas under the ROC curves were 0.96 (95%CI was 0-1.0) and 0.942 (95% CI was 0.876-1.0), which were higher than CA199 alone (0.862, 95%CI was 0.748-0.975). There was a high improvement in diagnostic sensitivity and accuracy when miR-210 and miR-25 were combined with CA19-9, respectively.

CONCLUSIONSPlasma miR-21, miR-155, miR-25, miR-210 have diagnostic value for pancreatic cancer, and deserve further study.

Aged ; Biomarkers, Tumor ; blood ; genetics ; CA-19-9 Antigen ; blood ; Case-Control Studies ; Female ; Humans ; Male ; MicroRNAs ; blood ; Middle Aged ; Pancreatic Neoplasms ; blood ; diagnosis ; genetics ; ROC Curve ; Real-Time Polymerase Chain Reaction

Objective The aim of this study was to identify six miRNAs expressed in plasma of patients with pancreatic cancer ( PCa ) and analyze their value as a diagnostic index of pancreatic cancer . Methods Plasma total RNAs were extracted from 30 PCa patients and 26 normal controls, and the abundance of six microRNAs was measured using real-time PCR.The possibility to combine them with CA19-9 as diagnostic biomarkers was analyzed .Results The expression level of miR-21, miR-210, miR-155, miR-20a, miR-25 and miR-196a in plasma of patients with pancreatic cancer were 1.65 ×106 , 5.98 × 104, 2.83 ×103, 3.47 ×106, 2.76 ×106, and 1.03 ×103 (copies/μl), while the normal controls were 4.08 ×105, 2.54 ×104, 8.55 ×102, 1.79 ×106, 9.32 ×105, and 4.67 ×102(copies/μl), respectively, with a significant difference between the two groups (P<0.05).The areas under the ROC curve of miR-21, miR-210, miR-155, miR-20a, miR-25 and miR-196a were 0.893, 0.810, 0.820, 0.766, 0.816 and 0.729, respectively.MiR-21 had the highest diagnostic value when it was used as diagnostic marker alone . The combination of miR-155 and miR-25 was more effective to distinguish PCa from normal than to be used alone, and the area under the ROC curve was 0.913(95%CI 0.838-0.988).When CA199 associated with miR-210 and miR-25, respectively, the areas under the ROC curves were 0.96 (95%CI was 0-1.0) and 0.942(95% CI was 0.876-1.0), which were higher than CA199 alone (0.862,95%CI was 0.748-0.975).There was a high improvement in diagnostic sensitivity and accuracy when miR-210 and miR-25 were combind with CA19-9, respectively.Conclusions Plasma miR-21, miR-155, miR-25, miR-210 have diagnostic value for pancreatic cancer , and deserve further study .

Objective The aim of this study was to identify six miRNAs expressed in plasma of patients with pancreatic cancer ( PCa ) and analyze their value as a diagnostic index of pancreatic cancer . Methods Plasma total RNAs were extracted from 30 PCa patients and 26 normal controls, and the abundance of six microRNAs was measured using real-time PCR.The possibility to combine them with CA19-9 as diagnostic biomarkers was analyzed .Results The expression level of miR-21, miR-210, miR-155, miR-20a, miR-25 and miR-196a in plasma of patients with pancreatic cancer were 1.65 ×106 , 5.98 × 104, 2.83 ×103, 3.47 ×106, 2.76 ×106, and 1.03 ×103 (copies/μl), while the normal controls were 4.08 ×105, 2.54 ×104, 8.55 ×102, 1.79 ×106, 9.32 ×105, and 4.67 ×102(copies/μl), respectively, with a significant difference between the two groups (P<0.05).The areas under the ROC curve of miR-21, miR-210, miR-155, miR-20a, miR-25 and miR-196a were 0.893, 0.810, 0.820, 0.766, 0.816 and 0.729, respectively.MiR-21 had the highest diagnostic value when it was used as diagnostic marker alone . The combination of miR-155 and miR-25 was more effective to distinguish PCa from normal than to be used alone, and the area under the ROC curve was 0.913(95%CI 0.838-0.988).When CA199 associated with miR-210 and miR-25, respectively, the areas under the ROC curves were 0.96 (95%CI was 0-1.0) and 0.942(95% CI was 0.876-1.0), which were higher than CA199 alone (0.862,95%CI was 0.748-0.975).There was a high improvement in diagnostic sensitivity and accuracy when miR-210 and miR-25 were combind with CA19-9, respectively.Conclusions Plasma miR-21, miR-155, miR-25, miR-210 have diagnostic value for pancreatic cancer , and deserve further study .

Objective The aim of this study was to detect the expression level of miR?29b in colorectal cancer ( CRC ) tissues and to analyze its relationship with clinicopathological features and prognosis. Methods The expression of miR?29b was detected by real?time quantitative PCR in 202 colorectal cancer tissues and adjacent colorectal tissues. Statistical analysis of the results was conducted using SPSS 16.0 software. Results The expression of miR?29b in colorectal cancer tissues and adjacent colorectal tissues was -7.761±0.115 and -7.150±0.137, respectively, with a significant difference between the two groups ( P<0.01) . Comparing colorectal cancer tissues with lymph node metastasis with those without lymph node metastasis, the expression of miR?29b (-7.528±0.158 vs. -7.988±0.164) was significantly increased (P<0.05). In addition, the expression of miR?29b in CRC according to TNM stage was -8.096±0.157 in stage Ⅰ/Ⅱ,-7.592±0.165 in stage Ⅲ and -6.603±0.468 in stageⅣpatients, showing a gradual increase depending on clinical staging ( P<0. 05 ) . Univariate Cox regression analysis indicated that lymph node metastasis, differentiation degree and TNM stage were significantly related to the postoperative survival of colorectal cancer patients ( P<0.001 ) . Multivariate Cox regression analysis indicated that differentiation degree and TNM stage were independent factors impacting the survival of colorectal cancer patients ( P<0.001) . Conclusions The expression level of miR?29b is reduced in colorectal cancer tissues compared with that in the adjacent colorectal tissues. High expression level of miR?29b is associated with lymph node metastasis and TNM stage of CRC. miR?29b may be a potential marker indicating colorectal cancer metastasis and malignant progression.

Objective The aim of this study was to detect the expression level of miR?29b in colorectal cancer ( CRC ) tissues and to analyze its relationship with clinicopathological features and prognosis. Methods The expression of miR?29b was detected by real?time quantitative PCR in 202 colorectal cancer tissues and adjacent colorectal tissues. Statistical analysis of the results was conducted using SPSS 16.0 software. Results The expression of miR?29b in colorectal cancer tissues and adjacent colorectal tissues was -7.761±0.115 and -7.150±0.137, respectively, with a significant difference between the two groups ( P<0.01) . Comparing colorectal cancer tissues with lymph node metastasis with those without lymph node metastasis, the expression of miR?29b (-7.528±0.158 vs. -7.988±0.164) was significantly increased (P<0.05). In addition, the expression of miR?29b in CRC according to TNM stage was -8.096±0.157 in stage Ⅰ/Ⅱ,-7.592±0.165 in stage Ⅲ and -6.603±0.468 in stageⅣpatients, showing a gradual increase depending on clinical staging ( P<0. 05 ) . Univariate Cox regression analysis indicated that lymph node metastasis, differentiation degree and TNM stage were significantly related to the postoperative survival of colorectal cancer patients ( P<0.001 ) . Multivariate Cox regression analysis indicated that differentiation degree and TNM stage were independent factors impacting the survival of colorectal cancer patients ( P<0.001) . Conclusions The expression level of miR?29b is reduced in colorectal cancer tissues compared with that in the adjacent colorectal tissues. High expression level of miR?29b is associated with lymph node metastasis and TNM stage of CRC. miR?29b may be a potential marker indicating colorectal cancer metastasis and malignant progression.

OBJECTIVETo explore the antitumor effect and toxicity of pegylated liposomal daunorubicin (PL-DNR) on leukemia.

METHODSPL-DNR was prepared by dry lipid hydration and remote loading, and its physicochemical indexes were analyzed. The inhibiting effect of PL-DNR on leukemia cells was observed in terms of in vitro cytotoxicity experiment. The therapeutic effect in vivo was assessed by tumor inhibition in leukemia L1210-bearing mice. Apoptosis in cardiomyocytes was detected using the terminal deoxynucleotidyl transferase mediated dUTP nick end labeling method (TUNEL staining).

RESULTSThe average diameter of PL-DNR was (110 ± 10)nm and the encapsulation efficiency was 94.21%. The in vitro cytotoxicity experiment showed that the inhibiting ability of PL-DNR in the treatment groups was continuously enhanced as the experiment proceeded. The in vivo pharmacodynamic experiment also indicated obvious tumor-inhibiting effect of PL-DNR. At the end of the experiment, the tumor volume of the PL-DNR group was (433.71 ± 234.77)mm(3), significantly smaller than that of (1 293.77 ± 381.26) mm(3) in the DNR group (P < 0.05). Moreover, the tumor weight of the PL-DNR group was (0.66 ± 0.29)g and that of the DNR group was (1.25 ± 0.43)g (P < 0.05). The myocardial toxicity experiment showed that the median apoptosis index of cardiomyocytes in the PL-DNR group was 13.83%, significantly lower than that of 42.67% in the DNR group (P < 0.05), indicating a lower toxicity of PL-DNR to the myocardium.

CONCLUSIONCompared with the free DNR, PL-DNR can improve the therapeutic effect on leukemia and reduce the.

Animals ; Antibiotics, Antineoplastic ; therapeutic use ; Apoptosis ; Daunorubicin ; therapeutic use ; Leukemia ; therapy ; Mice